Published in Gene Therapy Weekly, April 11th, 2002
The agreement with Geron covers the sale of a family of important patents covering process and compositional matter claims related to oligonucleotides containing phosphoramidate backbone linkages. N3-P5 phosphoramidate oligonucleotides are an important class of compounds being investigated for their use as therapeutic and diagnostic agents, as well as in other commercial applications.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.